Barry Sherman and Apotex Corporate Overview
Barry Sherman was the co-founder and former CEO of Apotex Inc., a Canadian pharmaceutical company headquartered in Toronto. He built Apotex into one of the largest generic drug manufacturers in North America, with operations spanning manufacturing, distribution, and regulatory compliance across multiple markets Forbes. The company focuses on producing affordable generic medications and active pharmaceutical ingredients for hospitals, pharmacies, and distributors in Canada and the United States.
Apotex operates under a corporate structure that includes multiple subsidiaries and research facilities. The company files regulatory submissions with agencies such as Health Canada and the U.S. Food and Drug Administration to maintain compliance for its product portfolio. Public business profiles describe Apotex as a vertically integrated generic pharmaceutical firm that manages its own production lines and distribution networks SEC.
Leadership, Ownership, and Corporate Governance
Barry Sherman served as the controlling figure in Apotex's ownership and strategic direction for decades. The company's governance structure includes executive leadership and board oversight roles that manage operations, finance, and regulatory affairs. Corporate filings and business profiles outline the ownership stakes and leadership hierarchy within Apotex and its affiliated entities.
Executive and Ownership Structure
Apotex's executive team includes individuals responsible for manufacturing, regulatory affairs, legal compliance, and finance. Ownership records indicate that the Sherman family held significant stakes in the company through private holding arrangements. The governance framework follows Canadian corporate law and internal policies that define decision-making authority and reporting lines Forbes.
Industry Position and Regulatory Context
Apotex competes in the generic pharmaceutical sector alongside other large manufacturers in Canada and the United States. The company's market position is shaped by its product approvals, manufacturing scale, and pricing strategies in the generic drug market. Regulatory filings and industry reports track Apotex's approvals, recalls, and compliance actions in both Canadian and U.S. markets SEC.
Regulatory Filings and Market Presence
Apotex submits drug applications and manufacturing updates to regulatory agencies to maintain its product approvals. The company's market presence includes distribution partnerships with pharmacies, hospitals, and wholesale distributors across North America. Business profiles and financial disclosures highlight Apotex's role in supplying affordable generic medications to public and private healthcare systems Forbes.